Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France.
Department of Cardiothoracic Surgery, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.
Int J Mol Sci. 2023 Sep 19;24(18):14277. doi: 10.3390/ijms241814277.
The discovery of miRNAs and their role in disease represent a significant breakthrough that has stimulated and propelled research on miRNAs as targets for diagnosis and therapy. Cardiovascular disease is an area where the restrictions of early diagnosis and conventional pharmacotherapy are evident and deserve attention. Therefore, miRNA-based drugs have significant potential for development. Research and its application can make considerable progress, as seen in preclinical and clinical trials. The use of miRNAs is still experimental but has a promising role in diagnosing and predicting a variety of acute coronary syndrome presentations. Its use, either alone or in combination with currently available biomarkers, might be adopted soon, particularly if there is diagnostic ambiguity. In this review, we examine the current understanding of miRNAs as possible targets for diagnosis and treatment in the cardiovascular system. We report on recent advances in recognising and characterising miRNAs with a focus on clinical translation. The latest challenges and perspectives towards clinical application are discussed.
miRNAs 的发现及其在疾病中的作用代表了一个重大突破,这激发并推动了 miRNA 作为诊断和治疗靶点的研究。心血管疾病是一个早期诊断和传统药物治疗受到限制且值得关注的领域。因此,基于 miRNA 的药物具有很大的发展潜力。研究及其应用可以取得可观的进展,正如临床前和临床试验所看到的那样。miRNA 的应用虽然仍处于实验阶段,但在诊断和预测各种急性冠状动脉综合征表现方面具有广阔的前景。它的使用,无论是单独使用还是与目前可用的生物标志物联合使用,都可能很快被采用,特别是在存在诊断模糊的情况下。在这篇综述中,我们探讨了 miRNA 作为心血管系统诊断和治疗靶点的最新认识。我们报告了最近在识别和表征 miRNA 方面的进展,重点是临床转化。讨论了 miRNA 临床应用的最新挑战和前景。